UNSPSC 51123112: Modecainide

This classification denotes an antiarrhythmic agent with the molecular formula C22H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) JU27887FWK, chemically known as benzamide, 4-hydroxy-3-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, ( but more generally known as modecainide, which bears US NIH Compound Identifier 54737. European Medicines Agency schedules Modecainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09028MIG.

UNSPSC 51123112 Modecainide is a Commodity code covering individual pharmaceutical products supplied to state and local health systems, emergency services, and public health agencies. State and local procurement activity under this code reflects purchasing of specific branded or generic medications for emergency medical services, hospital systems, and public health programs, often bundled with larger pharmaceutical supply contracts. The City of Tampa's IFB for Advanced Life Support Medications illustrates the scope: a sealed-bid procurement for four specific medication line items (Labetalol, Epinephrine, Adenosine, Diltiazem) to supply Tampa Fire Rescue, with firm pricing inclusive of delivery and warranty provisions covering defects and expiration-date management. Issuing bodies soliciting under this code span city fire and rescue departments, state health agencies, and cooperative purchasing alliances representing multiple state and local jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, uses the code to aggregate pharmaceutical procurement across participating state and local facilities, establishing master agreements with multiple manufacturers for generic and over-the-counter products distributed through authorized wholesalers.

Recent activity clusters in Florida and Minnesota, with additional state-level procurement signaled by Texas Health and Human Services Commission's exploratory Request for Information on direct-to-manufacturer prescription programs. The City of Tampa's IFB (26P00188) for Advanced Life Support Medications, posted April 24, 2026, with a bid deadline of April 8, 2026, carried a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount and an estimated contract value of $40,000; the contract term runs one year from award with two optional one-year renewals and three potential 30-day extensions. MMCAP's RFP (S1070000015802) for Generic Multi Source Pharmaceuticals and OTC Products, issued January 20, 2026, with proposals due March 26, 2026, sought manufacturers to provide comprehensive NDC-level product pricing for distribution across Minnesota, Oregon, and other participating jurisdictions through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative and technical compliance. Texas HHS's RFI (HHS0017013), posted April 3, 2026, represents early-stage market research on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements, signaling future procurement intent rather than immediate opportunity.